Det verkar som att du använder inkognito mode/privat surfningsläge eller en annonsblockerare, vilket kan försämra din upplevelse på webbplatsen. För en bättre upplevelse, inaktivera annonsblockerare och visa webbplatsen i icke-privat surfningsläge.
Neurological disorders are an important cause of disability and death worldwide.1
Globally, the burden of neurological disorders has increased substantially over the past 25 years because of expanding population numbers and ageing, despite substantial decreases in mortality rates from stroke and communicable neurological disorders.1
The number of patients who will need care by clinicians with expertise in neurological conditions will continue to grow in coming decades.2
Biomarkers for neurological disorders are urgently needed3
Neurological disorders, such as Alzheimer’s disease and other dementias, brain injury, Parkinson’s disease and others, would ideally exhibit a unique pathology to allow clinicians to distinguish particular conditions and give a reliable diagnosis and treatment.3
In reality, however, many neurodegenerative diseases share similar symptoms and features and the task of diagnosis is often challenging.3
Biomarkers are urgently needed to aid diagnosis, monitor disease progression and as new medicines are introduced, detect the patient’s response to treatment.3
At Roche we recognize the unmet need of patients affected by a neurological condition.
Discover what we do to support.
Alzheimer's disease (AD) is the most common form of dementia affecting millions of people worldwide.4,5 Confirming a diagnosis of mild cognitive impairment (MCI) and AD is important and often a relief for the individual and their loved ones.6
Biomarkers can support early and accurate diagnosis of MCI and AD, as biomarkers reflect the pathological accumulation of specific proteins in the brain.7